AR009145A1 - Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprenden - Google Patents
Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR009145A1 AR009145A1 ARP970105530A ARP970105530A AR009145A1 AR 009145 A1 AR009145 A1 AR 009145A1 AR P970105530 A ARP970105530 A AR P970105530A AR P970105530 A ARP970105530 A AR P970105530A AR 009145 A1 AR009145 A1 AR 009145A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- hydrogen
- guanidinyl
- alkanyl
- alpha
- Prior art date
Links
- -1 GUANIDINYL Chemical class 0.000 title abstract 9
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title abstract 3
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 2
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuestos heterocíclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores que comprenden la formula (I) donde R1 es hidrogeno, o alquiloo nada, enlace (a) es un doble enlace; (b) D es CR2 y R2 se selecciona del hidrogeno; alcanilo C1-C3 no sustituido, amino hidroxi, mercapto, alquitio oalcoxi C1-C3; alquilamino C1-C3 o dialquilamino C1-C3 y halogeno o cuando B es CR3; D puede ser N; (c) B es NR9, CR3=CR8, CR3=N, CR3, S, O SO, o SO2; donde R9se seleccion del hidrogeno, alcanilo, alquenilo o alquinilo C1-C3 no sustituido cicloalcanilo, cicloalquenilo y donde R3 y R8 se seleccionan independientementedel hidrogeno, alcanilo, alquenilo o alquinilo CC3 no sustituido; cicloalcanilo cicloalquenilo, alquiltio o alcoxi C1-C3no sustituido, hidroxi, tío, nitro,ciano, amino alquilamino C1-C3 o dialquilamino C1-C3 y halogeno; (d) R4, R5 y R6 se seleccionan independientemente del hidrogeno, alcanilo, alquenilo oalquinilo C1-C3 no sustituido, cicloalcanilo, cicloalquenilo,alquiltio o alcoxi C1-C3 no sustituido, hidroxi, tio, nitro, ciano, amino, alqulamino C1-C3y halo y NH-C(=NH3) NHR11 (guanidinilo) donde R10 y R11 se seleccionan independientemente del hidrogeno, metilo, y etilo; y donde uno y solo unode R4R5 y R6 es guanidinilo; (e) R7 se selecciona del hidrogeno, alcanilo, alquenilo o alquinilo C1-C3 no sustituido cicloalcanilo, cicloalquenilo, alquiltio oalcoxi C1-C3 no sustituido, hidroxi, tio, nitro, ciano, amino, alquilamino C1- C3 y halogeno; y enantiomeros, isomeros opticos, esteroisomeros, diastereomerossales adicionales, amidas y ésteres biohidrolizables y composiciones farmacéuticas que contienen dichos compuestos nuevos, y el uso de dichoscompuestos para la prevencion y el tratamiento de trastornos modulados por alfa-2 adrenoreceptores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3202396P | 1996-11-25 | 1996-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009145A1 true AR009145A1 (es) | 2000-03-08 |
Family
ID=21862692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970105530A AR009145A1 (es) | 1996-11-25 | 1997-11-25 | Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprenden |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6225331B1 (es) |
| EP (1) | EP0944604B1 (es) |
| JP (1) | JP2001506600A (es) |
| KR (1) | KR20000069131A (es) |
| CN (1) | CN1104422C (es) |
| AR (1) | AR009145A1 (es) |
| AT (1) | ATE286885T1 (es) |
| AU (1) | AU730369B2 (es) |
| BR (1) | BR9713536A (es) |
| CA (1) | CA2272640C (es) |
| CO (1) | CO4910148A1 (es) |
| CZ (1) | CZ184099A3 (es) |
| DE (1) | DE69732244T2 (es) |
| ES (1) | ES2236833T3 (es) |
| HU (1) | HUP0000312A3 (es) |
| ID (1) | ID23857A (es) |
| IL (1) | IL130077A0 (es) |
| NO (1) | NO313912B1 (es) |
| NZ (1) | NZ336010A (es) |
| PE (1) | PE16399A1 (es) |
| RU (1) | RU2194700C2 (es) |
| SK (1) | SK69799A3 (es) |
| TR (1) | TR199901468T2 (es) |
| WO (1) | WO1998023596A1 (es) |
| ZA (1) | ZA9710578B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2272640C (en) | 1996-11-25 | 2003-07-08 | The Procter & Gamble Company | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| US6291514B1 (en) * | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
| DZ3415A1 (fr) * | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| WO2002019996A2 (en) * | 2000-09-08 | 2002-03-14 | Warner-Lambert Compan Llc | Prevention of acute sinusitis and sinus attack |
| DE60216747T2 (de) * | 2001-04-09 | 2007-10-04 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten |
| US20030207814A1 (en) * | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
| US20050124652A1 (en) * | 2002-02-04 | 2005-06-09 | Rustum Boyce | Guanidino compounds |
| US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
| WO2003072056A2 (en) * | 2002-02-25 | 2003-09-04 | Chiron Corporation | Intranasal administration of mc4-r agonists |
| EP1551834B1 (en) * | 2002-05-23 | 2010-08-25 | Novartis Vaccines and Diagnostics, Inc. | Substituted quinazolinone compounds |
| CA2523015A1 (en) | 2003-05-23 | 2004-12-29 | Chiron Corporation | Guanidino-substituted quinazolinone compounds as mc4-r agonists |
| RU2254855C2 (ru) * | 2003-09-10 | 2005-06-27 | Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" | Противовирусное средство и способ его получения |
| WO2005051391A1 (en) * | 2003-11-19 | 2005-06-09 | Chiron Corporation | Quinazolinone compounds with reduced bioaccumulation |
| KR20130136010A (ko) * | 2005-04-13 | 2013-12-11 | 네우렉슨 인코포레이티드 | Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물 |
| RU2008122978A (ru) | 2005-11-09 | 2009-12-20 | Комбинаторкс, Инкорпорейтед (Us) | Способы, композиции и наборы для лечения медицинских состояний |
| CL2008000838A1 (es) * | 2007-03-23 | 2008-10-10 | Neuraxon Inc | Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios |
| CA2705833A1 (en) * | 2007-11-16 | 2009-05-22 | Subhash C. Annedi | 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| EP2370136A4 (en) * | 2008-12-01 | 2015-12-30 | Map Pharmaceuticals Inc | INHALATIVE RELEASE PROCEDURES AND DEVICES |
| US8555875B2 (en) | 2008-12-23 | 2013-10-15 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| GB0919889D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
| EP2668177B1 (en) * | 2011-01-28 | 2014-10-22 | Boehringer Ingelheim International GmbH | Substituted pyridinyl-pyrimidines and their use as medicaments |
| CN112047947A (zh) * | 2020-10-13 | 2020-12-08 | 石药集团新诺威制药股份有限公司 | 一种茶碱的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU148414A1 (ru) * | 1961-07-03 | 1961-11-30 | Е.Н. Зильберман | Способ получени имидазолов и оксазолов |
| US3908013A (en) | 1970-09-17 | 1975-09-23 | Armour Pharma | Pharmaceutical aromatic guanidine compositions and methods of using same |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US3947455A (en) | 1974-04-15 | 1976-03-30 | Armour Pharmaceutical Company | 5'-(8'-Hydroxyquinolyl)guanidine compounds |
| US4000279A (en) | 1974-10-29 | 1976-12-28 | Armour Pharmaceutical Company | Pharmaceutical preparations containing 5'-(8'-hydroxyquinolyl)guanidine compounds and methods of using same |
| KR860002082A (ko) * | 1984-08-29 | 1986-03-26 | 프랑시스 글로리 | 자기 변환기 헤드 구조물 |
| NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| JPH09506622A (ja) * | 1993-12-17 | 1997-06-30 | ザ、プロクター、エンド、ギャンブル、カンパニー | α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物 |
| US5478858A (en) | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| CA2272640C (en) | 1996-11-25 | 2003-07-08 | The Procter & Gamble Company | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| EP0946523A1 (en) * | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
-
1997
- 1997-11-21 CA CA002272640A patent/CA2272640C/en not_active Expired - Fee Related
- 1997-11-21 AT AT97948290T patent/ATE286885T1/de not_active IP Right Cessation
- 1997-11-21 ES ES97948290T patent/ES2236833T3/es not_active Expired - Lifetime
- 1997-11-21 RU RU99113446/04A patent/RU2194700C2/ru not_active IP Right Cessation
- 1997-11-21 ID IDW990410A patent/ID23857A/id unknown
- 1997-11-21 IL IL13007797A patent/IL130077A0/xx unknown
- 1997-11-21 EP EP97948290A patent/EP0944604B1/en not_active Expired - Lifetime
- 1997-11-21 HU HU0000312A patent/HUP0000312A3/hu unknown
- 1997-11-21 BR BR9713536-4A patent/BR9713536A/pt not_active IP Right Cessation
- 1997-11-21 DE DE69732244T patent/DE69732244T2/de not_active Expired - Lifetime
- 1997-11-21 AU AU54381/98A patent/AU730369B2/en not_active Ceased
- 1997-11-21 CN CN97181078A patent/CN1104422C/zh not_active Expired - Fee Related
- 1997-11-21 JP JP52469498A patent/JP2001506600A/ja active Pending
- 1997-11-21 NZ NZ336010A patent/NZ336010A/en unknown
- 1997-11-21 US US09/308,788 patent/US6225331B1/en not_active Expired - Lifetime
- 1997-11-21 WO PCT/US1997/020802 patent/WO1998023596A1/en not_active Ceased
- 1997-11-21 TR TR1999/01468T patent/TR199901468T2/xx unknown
- 1997-11-21 KR KR1019997004619A patent/KR20000069131A/ko not_active Ceased
- 1997-11-21 CZ CZ991840A patent/CZ184099A3/cs unknown
- 1997-11-21 SK SK697-99A patent/SK69799A3/sk unknown
- 1997-11-24 CO CO97068606A patent/CO4910148A1/es unknown
- 1997-11-25 PE PE1997001070A patent/PE16399A1/es not_active Application Discontinuation
- 1997-11-25 AR ARP970105530A patent/AR009145A1/es unknown
- 1997-11-25 ZA ZA9710578A patent/ZA9710578B/xx unknown
-
1999
- 1999-05-25 NO NO19992498A patent/NO313912B1/no unknown
-
2000
- 2000-12-01 US US09/727,900 patent/US6391878B2/en not_active Expired - Lifetime
-
2002
- 2002-02-08 US US10/071,284 patent/US20020128481A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009145A1 (es) | Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprenden | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR013184A1 (es) | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis | |
| ES2144403T3 (es) | Derivados de tiazol como inhibidores de oxigeno activo. | |
| NO20005237D0 (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
| CO4910149A1 (es) | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoceptores | |
| PE20070135A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| ECSP941096A (es) | Procedimiento para la preparacion de un derivado indol | |
| ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| PE20040120A1 (es) | Derivados de quinolina como antagonistas de npy | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| TR200000671T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler. | |
| TR200000670T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
| AR022019A1 (es) | Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen | |
| AR024390A1 (es) | Nuevos compuestos | |
| ES2107212T3 (es) | Derivados de 1,4-benzoxazina como abridores de los canales de potasio. | |
| CO4910150A1 (es) | Compuestos de 2-imidazolinilaminobenzoxazol utiles con agonistas de alfa-2 adrenoceptores | |
| UY24010A1 (es) | Nuevos pirrolocarbazoles | |
| NO20074346L (no) | Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| ES2249636T3 (es) | Triazoles como antagonistas de la oxitocina. | |
| AR009144A1 (es) | Compuestos heterociclicos guanidilamino, composicion farmaceutica que comprende dicho compuesto y uso del mismo para la fabricacion de un medicamento | |
| CO4910166A1 (es) | Compuestos 2-imidazolinilaminoindazol utiles como agonistas de 2-alfa adrenoceptores | |
| AR027349A1 (es) | Derivados de amidas heterociclicas | |
| AR010644A1 (es) | Compuesto 2-imidazolinilaminobenzotiazol, composicion farmaceutica que comprende dicho compuesto y uso del mismo para la fabricacion de un medicamento | |
| MXPA05007497A (es) | Derivados de acidos indenocarboxilicos y su uso para el tratamiento y prevencion de diabetes y dislipidemia. |